Cook MyoSite, Inc., a Cook Group subsidiary established in 2002, develops muscle-derived cell therapies and manufactures human muscle cell products for research and clinical development. Based in Pittsburgh, the company also provides contract manufacturing and research services grounded in more than two decades of muscle-cell technology experience.
United Network for Organ Sharing (UNOS) Registration
Registration
Institutional Review Board (IRB)-Approved Tissue Collection Protocols
Compliance program
IRB
Quality certification
Noveome Biotherapeutics, IncNoveome Biotherapeutics is a Pittsburgh-based clinical-stage biopharmaceutical company developing ST266, a non-cellular biologic derived from the secretome of cultured amnion-derived epithelial cells. Its scalable GMP process produces the investigational biologic for research and clinical development across challenging diseases and conditions, with the company describing activity in clinical and preclinical studies.PITTSBURGH, PA
Lifeline Cell TechnologyLifeline Cell Technology develops and manufactures purified primary human cells, stem-cell products, and optimized cell-culture media for laboratory research. Its founders helped introduce normal human cell systems more than 25 years ago, and the company now operates an 8,000-square-foot laboratory and administrative facility in Frederick, Maryland as a wholly owned subsidiary of International Stem Cell Corporation. Lifeline also supports researchers through scientist-led technical assistance and an international distributor network.FREDERICK, MD
Kite PharmaKite Pharma is a cell therapy company founded in 2009 as a pioneer in cell therapy research. It researches, develops, manufactures, and commercializes cell therapies, including CAR T-cell therapies, and opened its commercial manufacturing site in El Segundo in 2016. Acquired by Gilead Sciences in 2017, Kite operates as an independent operating company within Gilead.FREDERICK, MD
MesoblastFounded in 2004 by physician-scientist Silviu Itescu, Mesoblast develops and manufactures allogeneic, off-the-shelf cellular medicines for severe inflammatory and tissue-damage conditions. Its proprietary mesenchymal lineage cell platform supports Ryoncil, the first FDA-approved mesenchymal stromal cell therapy, while the company advances additional therapies through operations in Australia, the United States and Singapore. Mesoblast’s manufacturing approach is designed for industrial-scale production of cryopreserved cell products without donor-recipient matching.NEW YORK, NY